Two new trials presented here at ESMO Congress 2019 strengthen the case for using CDK4/6 inhibitors plus endocrine therapy in patients with HR-positive/HER2 negative advanced breast cancer. The Monarch 2 study evaluated abemaciclib plus fulvestrant in pre, peri and post-menopausal women with HR-positive/HER2 negative advanced breast cancer that had progressed despite endocrine therapy. The results ...
Evidence builds for CDK4/6 inhibitors in advanced breast cancer
By Nicola Garrett
30 Sep 2019